CDC: Ninth Welder’s Anthrax Survivor Treated with Obiltoxaximab

In a Morbidity and Mortality Weekly Report published January 1, 2026, the Centers for Disease Control and Prevention and the Louisiana Department of Health detailed the ninth recorded U.S. case of welder’s anthrax, a severe pneumonia caused by anthrax‑toxin‑producing Bacillus cereus group bacteria. The patient, an otherwise healthy 18‑year‑old welding apprentice in Louisiana, survived after receiving multidrug antimicrobial therapy, pleural drainage, mechanical ventilation, and obiltoxaximab supplied from the U.S. Strategic National Stockpile.

Clinicians first notified public health authorities on September 7, 2024, after the patient was hospitalized with rapidly progressive respiratory failure. Approximately one week after symptom onset, clinicians suspected welder’s anthrax. Thirty‑four hours after that clinical suspicion, the patient received obiltoxaximab; within 72 hours he improved enough to be extubated and to discontinue mechanical ventilation. He underwent drainage of a pleural effusion, received prolonged inpatient care including empiric antibiotics, vancomycin, meropenem, ciprofloxacin, and doxycycline, and was discharged after 26 days. At a three‑month follow‑up he remained free of pulmonary symptoms.

Laboratory testing conducted by the Louisiana Department of Health and CDC detected anthrax toxin genes in the patient’s blood and in environmental samples taken from his worksite, supporting an occupational exposure. The MMWR authors note that the investigation and clinical response were coordinated between the treating team, state health authorities, and CDC; the agency determined the activity to be not research and consistent with applicable federal policy.

This instance marks the first documented clinical use of obiltoxaximab for an anthrax‑like disease. Of nine known U.S. cases of welder’s anthrax, three patients have survived and six have died; of the survivors, two, including the Louisiana patient, received an anthrax antitoxin. An earlier survivor received raxibacumab, another monoclonal antitoxin. None of the six fatal cases received antitoxin. The report highlights that rapid recognition, early initiation of recommended multidrug antibiotics, timely drainage of pleural effusions, and prompt access to antitoxin likely contributed to survival in the recent case.

Investigators place this case in a broader occupational context. Previous CDC reviews covering 1994–2020 documented seven cases clustered among welders and metalworkers, and noted evidence that welding fumes can impair respiratory immune defenses. In several past cases, clinical isolates matched environmental samples from worksites, implicating workplace exposures. Some patients with available hematocrit data had levels suggesting iron overload, a condition that may alter host susceptibility.

Public‑health experts say the report reinforces the need for heightened clinical suspicion for severe necrotizing pneumonia in metalworkers, improved workplace controls to limit inhalation of dust and fumes, and streamlined mechanisms to obtain antitoxin from national stockpiles. As the Gulf Coast and southwestern regions continue to report cases linked to metalworking, the MMWR calls for strengthened occupational surveillance, rapid laboratory testing for anthrax toxin genes, and coordinated response pathways to reduce preventable deaths among welders.